UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising
approach to improve the efficacy of EGFR-TKIs in the treatment
of NSCLC patients
Authors*: Niki Karachaliou, Imane Chaib, Sara Piloeo, Jordi Codony, Xueting Cai, Xuefei Li, Ana Drozdowskyj,
Carles Codony, Andrés Felipe Cardona, Guillermo López-Vivanco, Alain Vergnenègre, José Miguel Sánchez,
Mariano Provencio, Filippo de Marinis, Enric Carcereny, Noemí Reguart, Rosario García-Campelo, Silvia Marin,
Cristina Teixidó, Isabella Sperduti, Sonia Rodríguez, Roger Estrada, Raimon Puig de la Bellacasa,
José Luis Ramírez, Miguel Angel Molina-Vila, Caicun Zhou, Peng Cao, Patrick Ma, Trever Bivona, Rafael Rosell.
Pres #: 265 Section: 15 Presentation Date/Time: Sunday, April 17: 1:00-5:00PM
Location:
Presentation Type: Poster Session
Bivona Lab Expertise: Our team uses the tools of precision medicine to improve the molecular diagnosis and
targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying
and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient
samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy
resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic
and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung
cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for
novel clinical trials we are launching to improve patient survival.
http://www.bivonalab.net/
__________________________________________________________________________
EGFR inhibition generates drug tolerant persister cells by blocking
AKT activity and thus inactivating Ets-1 function
Authors*: Janyaporn Phuchareon, David W. Eisele, Frank McCormick, Osamu Tetsu
Pres #: 293 Section: 16 Presentation Date/Time: Sunday, April 17: 1:00-5:00PM
Location:
Presentation Type: Poster Session
Tetsu Lab Expertise: The Tetsu Laboratory is interested in the mechanisms underlying initiation and
progression of various malignancies originated from endoderm; lung, colon and pancreatic cancers.
They have exploited the cell signaling pathways that make the cancers different from normal tissues.
More recently, their research interests have focus on drug resistance to EGFR and Ras inhibitors. In order
to establish truly effective treatments, they have proposed a multi-drug combination therapy targeting
the origin of acquired resistant cells, as reduction of this subset may prevent emergent resistance to the
kinase inhibitors. In this era of precision medicine, they intend to design the most relevant combination
to overcome the patient-specific drug resistance.
*UCSF authors in bold
10